drug-discovery-pipeline

Multi-agent analysis ranks drug repurposing candidates by spawning domain expert agents across chemistry, target validation, ADMET, and safety to independently evaluate candidates before synthesizing their evidence into a weighted consensus ranking.

Consensus ranking in drug discovery resolves conflicts by detecting disagreements across multi-agent evaluations, running a devil's advocate challenge to test findings, and synthesizing the results into a weighted consensus recommendation for drug candidates.

Yes, multi-agent orchestration for drug discovery runs without external dependencies by utilizing internal domain expert agents to assess chemistry, oncology context, ethnobotany, and disease biology to generate structured clinical feasibility recommendations.

To assess ADMET properties and safety for oral mucositis treatments, the pipeline deploys specialized agents that evaluate absorption, distribution, metabolism, excretion, and toxicity alongside clinical disease-phase coverage to determine viability.

Evaluating clinical feasibility and combination potential for repurposed drugs involves synthesizing parallel expert assessments into a structured path-to-patients report that includes combination recommendations and a practical assessment of clinical viability.

A knowledge graph is needed for drug repurposing pipelines when structuring complex relationships across chemistry, disease biology, and target validation data to enable multi-agent orchestration and evidence synthesis for final ranked outputs.